Ignite Creation Date:
2025-12-24 @ 9:26 PM
Ignite Modification Date:
2025-12-29 @ 11:57 PM
Study NCT ID:
NCT01029132
Status:
COMPLETED
Last Update Posted:
2016-01-06
First Post:
2009-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Characteristics of Treatment Responders to Galantamine
Sponsor:
Samsung Medical Center
Organization:
Study Overview
Official Title:
Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the characteristics of treatment responders to galantamine.
Detailed Description:
The purposes of this study are:
1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.
2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.
1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.
2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: